WHO of­fi­cial un­der fire af­ter al­le­ga­tions of racism, leak­ing sen­si­tive da­ta — re­port

4 years ago
Pharma

Covid-19 roundup: Watch­dog crit­i­cizes EU Com­mis­sion over pres­i­den­t's texts; No­vavax signs vac­cine deal with Is­rael

4 years ago
Coronavirus

Rob Calif­f's nom­i­na­tion to be the next FDA com­mis­sion­er is now in se­ri­ous lim­bo

4 years ago
FDA+

Up­dat­ed: JAK woes con­tin­ue as Eli Lil­ly warns of pos­si­ble Olu­mi­ant CRL for atopic der­mati­tis and re­ports PhI­II fail ...

4 years ago
R&D
FDA+

Ox­ford Bio­med­ica en­ters the AAV man­u­fac­tur­ing world, buy­ing Ho­mol­o­gy's in-house busi­ness

4 years ago
Deals
Cell/Gene Tx

Blue­print Med­i­cines gets more ducks in a row be­fore CEO tran­si­tion; Paul Stof­fels has his work cut out for him at ...

4 years ago
Peer Review

Un­der the gun with Aduhelm floun­der­ing, Bio­gen sells its stake in biosim­i­lars busi­ness for $2.3B

4 years ago
Deals

Am­gen, Re­gen­eron and oth­ers seek more de­tail from FDA on re­al-world da­ta plans

4 years ago
Pharma
FDA+

FDA of­fers new guid­ance to help gener­ic drug de­vel­op­ers get to mar­ket more quick­ly

4 years ago
Pharma
FDA+

Reign­ing cys­tic fi­bro­sis champ Ver­tex wows an­a­lysts, again — but can a heavy­weight con­tender de­liv­er a blow?

4 years ago
Pharma

Biotech gets burned at a fire­side chat as CEO re­veals FDA clamped a hold on its can­cer drug, now un­der re­view

4 years ago
FDA+

Scott Got­tlieb crit­i­cizes CMS in feud over Aduhelm cov­er­age, calls out their lack of ex­per­tise

4 years ago
Pharma

With the CDC un­der fire for mixed mes­sages again, can new com­mu­ni­ca­tion strate­gies help re­coup pub­lic trust?

4 years ago
Pharma
Marketing

Fu­ji­film ex­pands in US af­ter $100M deal for Atara's man­u­fac­tur­ing site and em­ploy­ees

4 years ago
Pharma
Manufacturing

Law pro­fes­sors join fight against J&J's con­tro­ver­sial move to spin out talc as­sets and file for bank­rupt­cy

4 years ago
Pharma

Can new man­u­fac­tur­ing ap­proach­es fi­nal­ly make a decades-old cell ther­a­py idea a re­al­i­ty?

4 years ago
Cell/Gene Tx
Manufacturing

To ex­pand its oral and top­i­cal dosage op­tions, Catal­ent will put $10M in­to mi­croniza­tion

4 years ago
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Brazil to man­u­fac­ture Vaxzevria at home; As­traZeneca ramp up in Spain gets the OK

4 years ago
Manufacturing

One­Touch di­a­betes brand up­dates its play­book with ex-NFL spokesper­son and dig­i­tal lifestyle one-stop shop

4 years ago
Pharma
Marketing

Keytru­da for HIV? Re­searchers claim it's a pos­si­bil­i­ty — open­ing more doors to­ward cure

4 years ago
R&D
Pharma

Covid-19 roundup: Mod­er­na kicks off tri­al for Omi­cron-spe­cif­ic vac­cine; EMA signs off on Pfiz­er pill

4 years ago
Coronavirus

Zio­pharm re­brands to Alaunos, clos­es Boston of­fice with new CEO at the reins

4 years ago
Pharma

With Forty Sev­en co-founder at the helm, new biotech spin­out launch­es to tar­get mu­ta­tions po­ten­tial­ly linked to ...

4 years ago
Financing
Startups

Go­ing af­ter an old GSK tar­get in a new way, a Yale spin­out hits the clin­ic and nabs a mod­est raise

4 years ago
Financing
First page Previous page 592593594595596597598 Next page Last page
A service from the Financial Times